Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 3
2022 5
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Cross-resistance and drug sequence in prostate cancer.
Buck SAJ, Koolen SLW, Mathijssen RHJ, de Wit R, van Soest RJ. Buck SAJ, et al. Drug Resist Updat. 2021 May;56:100761. doi: 10.1016/j.drup.2021.100761. Epub 2021 Mar 18. Drug Resist Updat. 2021. PMID: 33799049 Free article. Review.
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, Lorch A, Heidenreich A, Tsaur I, Larcher-Senn J, Buck SAJ, Mathijssen RHJ, Jaehde U, Gillessen S, Joerger M. Omlin A, et al. Among authors: buck saj. Clin Cancer Res. 2023 May 15;29(10):1887-1893. doi: 10.1158/1078-0432.CCR-22-3360. Clin Cancer Res. 2023. PMID: 36917691 Clinical Trial.
Influence of Darolutamide on Cabazitaxel Systemic Exposure.
Buck SAJ, Guchelaar NAD, de Bruijn P, Ghobadi Moghaddam-Helmantel IM, Oomen-de Hoop E, Westgeest HM, Hamberg P, Mathijssen-van Stein D, Lolkema MP, Koolen SLW, de Wit R, Mathijssen RHJ. Buck SAJ, et al. Clin Pharmacokinet. 2022 Oct;61(10):1471-1473. doi: 10.1007/s40262-022-01159-6. Epub 2022 Jul 27. Clin Pharmacokinet. 2022. PMID: 35895277 No abstract available.
Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia.
Agema BC, Buck SAJ, Viskil M, Isebia KT, de Neijs MJ, Sassen SDT, Koch BCP, Joerger M, de Wit R, Koolen SLW, Mathijssen RHJ. Agema BC, et al. Among authors: buck saj. Eur Urol Oncol. 2023 Nov 2:S2588-9311(23)00231-6. doi: 10.1016/j.euo.2023.10.015. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37925350 Free article.
Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment.
Buck SAJ, Braal CL, Hofman MM, Oomen-de Hoop E, de Bruijn P, Ghobadi Moghaddam-Helmantel IM, Hussaarts KGAM, Vastbinder MB, van Rossum-Schornagel QC, van Schaik RHN, Jager A, Koolen SLW, Mathijssen RHJ. Buck SAJ, et al. Ther Adv Med Oncol. 2022 Mar 17;14:17588359221081075. doi: 10.1177/17588359221081075. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35321309 Free PMC article.
Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
Buck SAJ, Talebi Z, Drabison T, Jin Y, Gibson AA, Hu P, de Bruijn P, de Ridder CMA, Stuurman D, Hu S, van Weerden WM, Koolen SLW, de Wit R, Sparreboom A, Mathijssen RHJ, Eisenmann ED. Buck SAJ, et al. Int J Cancer. 2024 Mar 16. doi: 10.1002/ijc.34922. Online ahead of print. Int J Cancer. 2024. PMID: 38491867
CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients.
Isebia KT, Mostert B, Belderbos BPS, Buck SAJ, Helmijr JCA, Kraan J, Beaufort CM, Van MN, Oomen-de Hoop E, Sieuwerts AM, van IJcken WFJ, van den Hout-van Vroonhoven MCGN, Brouwer RWW, Oole E, Hamberg P, Haberkorn BCM, Helgason HH, de Wit R, Sleijfer S, Mathijssen RHJ, Martens JWM, Jansen MPHM, van Riet J, Lolkema MP. Isebia KT, et al. Among authors: buck saj. Eur J Cancer. 2022 Dec;177:33-44. doi: 10.1016/j.ejca.2022.09.032. Epub 2022 Oct 6. Eur J Cancer. 2022. PMID: 36323051 Free article.
16 results